Xinhong Life Sciences Secures Tens of Millions RMB in Pre-A+ Round Led by Mingxi Capital to Advance Innovative Ultrasound-Based Cardiovascular Device Commercialization

VCBeat has learned that recently,ScieHomeCompleted tens of millions of RMB in Pre-A+ round financing, led byMingxi CapitalSole Lead Investor.

ScieHome, established in June 2022, is an innovative cardiovascular medtech company dedicated to building a platform based on ultrasonic energy technology and combined drug-device technologies. Its globally first-of-its-kind ultrasound-assisted thrombectomy system is built upon the company’s proprietary multi-directional pulsed ultrasound technology.Specifically developed for current refractory, mixed venous thrombosis, this device enables rapid clearance of polymorphic mixed thrombi. The dosage of thrombolytic agents required is less than one-quarter of that used in conventional Catheter-Directed Thrombolysis (CDT), significantly reducing the risk of bleeding while preserving the vascular intima and venous valves.The product is currently in mid-stage clinical trials. This financing round will accelerate the industrialization and commercialization of this product, as well as the development of subsequent integrated interventional ultrasound diagnosis and treatment products.

Venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most lethal vascular disease after coronary heart disease and stroke. DVT and PE represent different stages of the same disease process. DVT commonly occurs in the lower extremities, and its major adverse outcomes are pulmonary embolism (PE) and post-thrombotic syndrome (PTS). The mortality rate for acute PE is as high as 20–30%. If acute DVT is not diagnosed and treated promptly, it can progress to chronic DVT. Impaired venous return in the limbs can lead to a series of symptoms collectively known as post-thrombotic syndrome (PTS), including lower extremity swelling, pain, skin hyperpigmentation, and even refractory skin ulcers. Within two years, 30–50% of patients with DVT develop PTS. Once PTS occurs, the amputation rate reaches 10–30%.

Both PE and PTS are highly perilous, with extremely high rates of mortality and disability; therefore, the prevention and treatment of DVT are urgently needed.However, due to the insidious onset of deep vein thrombosis (DVT), which often leads to delayed treatment, most patients present at hospitals with mixed thrombi characterized primarily by acute thrombosis superimposed on subacute or even chronic thrombosis. Current mainstream therapies demonstrate unsatisfactory efficacy in removing such thrombi. Consequently, acute DVT complicated by subacute or chronic thrombosis has become a key challenge and focus in this field.

With the advancement of technology, ultrasound-assisted thrombolysis, with its unique therapeutic concept, holds promise for addressing this challenge.Ultrasound technology separates and disrupts fibrin chains through the cavitation effect, thereby exposing more drug receptor sites. Additionally, by inducing a microflow environment, it enhances the penetration of thrombolytic agents into thrombi, delivering drugs deeper into the clot. This accelerates thrombolysis with reduced drug dosage, achieving safe and effective clot dissolution.

With evolving treatment paradigms in thrombus removal, vascular protection, and vascular rehabilitation, ultrasound-assisted thrombolysis is poised to become a key future direction in the field of thrombectomy. Leveraging its leading advantages and technological barriers, ScieHome has launched its independently innovated integrated multi-directional pulsed ultrasound-assisted thrombectomy system, embodying this forward-looking therapeutic concept. The company’s achievement of securing tens of millions of yuan in financing twice within a single year further underscores the capital market’s strong recognition of ScieHome’s team, innovative technologies, and product prospects.

ScieHome’s founding team possesses rare R&D and industrialization experience in China,The company’s founder previously served as the project lead for MicroPort’s flagship coronary product, the Firehawk™ Targeted Elution Drug-Eluting Stent System, and brings nearly 20 years of experience in R&D and management within the industry. The core founding team possesses extensive industrial and entrepreneurial expertise spanning ultrasonic energy R&D, synergy between pharmaceuticals and medical devices, regulatory and quality management, product commercialization, and startup operations., with over 10 years of executive experience at renowned domestic and international companies such as MicroPort Medical and Philips Healthcare, is a founding team characterized by strong innovation and industrialization capabilities.

Centering on interventional ultrasound and drug-device synergy,ScieHome has established a series of technological platforms, including interventional ultrasound energy technology, combined drug-device technology, hardware and circuit design technology, software and algorithm architecture technology, and an industrial translation platform.Continuously develop innovative energy-based medical devices that truly address clinical pain points.

Wu Changsheng, Founder of ScieHomeStatement: It is a great honor to partner with an institution with strong industrial backgrounds such as Mingxi Capital. We sincerely thank both new and existing shareholders for their recognition and support of ScieHome, and extend special gratitude to our capable, efficient, pragmatic, and steady ScieHome team. The company’s first ultrasound-assisted thrombectomy system has already demonstrated its unique clinical advantages. This financing round will accelerate the clinical development and commercialization of this product, expedite its market launch, and rapidly advance the development of subsequent innovative interventional ultrasound products. Interventional ultrasound technology is a highly cutting-edge and promising medical field. Guided by clinical pain points and scenario-specific needs, the company will continue to focus on interventional ultrasound technology, iteratively launching innovative products to benefit a broad patient population.

Mingxi CapitalIt indicates that the cardiovascular sector is one of the medical device sub-sectors with the largest scale and potential, and it is a key focus area for Mingxi Capital. Venous thromboembolism (VTE) is the third leading cause of cardiovascular death, after coronary heart disease and stroke. ScieHome’s flagship product, an ultrasound-assisted thrombectomy device, addresses clinical pain points associated with deep vein thrombosis; it has currently entered the clinical trial stage with significant clinical efficacy. The company’s other products, which leverage innovative interventional ultrasound technology to address unmet clinical needs, are scheduled to sequentially enter type testing and clinical trials. These products have the potential to achieve global first-of-kind regulatory approval, indicating enormous market potential. In the future, Mingxi Capital will leverage the industrial and capital resources of its co-initiators to support the company’s development.

Mingxi Capital is a professional healthcare investment firm jointly established by the listed company Mingde Biology and Legend Capital. Focusing on investments in the healthcare sector, it prioritizes sub-sectors such as diagnostic devices, life sciences, and consumer health. Guided primarily by fund returns, Mingxi Capital maximizes investment returns through market-oriented operations and proactive industrial empowerment. Leveraging the industrial and capital advantages of its shareholders, Mingxi Capital is committed to fostering the next industry leaders in the life and health sectors through industrial empowerment and capital support.